187 filings
Page 3 of 10
8-K
4nhzdwfyb5kh3pn6c vk
8 Nov 22
Spero Therapeutics Announces Closing of Exclusive License Agreement with GSK for Tebipenem HBr
8:12am
8-K
0k4qx15fvc rfkoaaz
22 Sep 22
GSK and Spero Therapeutics Announce Exclusive License Agreement for Late-Stage Antibiotic Asset, Tebipenem HBr
8:00am
8-K
3693kuai
19 Sep 22
Departure of Directors or Certain Officers
5:14pm
8-K
1y9v6gem
6 Sep 22
Spero Therapeutics Provides Tebipenem HBr Program Update Following Type A Meeting with the U.S. Food and Drug Administration
8:15am
8-K
fb14cvr1d5dmgz
10 Aug 22
Spero Therapeutics Announces Second Quarter 2022 Operating Results and Provides Business Update
4:09pm
DEFA14A
321tsfk pwejr7de
5 Aug 22
Additional proxy soliciting materials
4:08pm
8-K
zld7cuq3lbzd
1 Jul 22
Departure of Directors or Certain Officers
4:06pm
8-K
3agirz6x58ceq5ie a9
27 Jun 22
Spero Therapeutics Receives Complete Response Letter from U.S. Food and Drug Administration for Tebipenem HBr New Drug Application
4:11pm
8-K
hguxl7odb
7 Jun 22
Termination of a Material Definitive Agreement
4:01pm
8-K
77j63f2oh2jp3f52
16 May 22
Spero Therapeutics Announces First Quarter 2022 Operating Results and Provides Business Update
4:10pm
8-K
ica80a
3 May 22
Spero Therapeutics Announces New Strategic Direction Focusing on Advancing Promising Clinical-Stage Pipeline
7:15am
8-K
ozjn mygyaln2hp6s
6 Apr 22
Spero Therapeutics Tebipenem Pivoxil Hydrobromide Phase 3 Data Published in The New England Journal of Medicine
5:47pm
8-K
bj4ue
31 Mar 22
Spero Therapeutics Announces Fourth Quarter and Full Year 2021 Operating
4:16pm
8-K
kbd1j5b9
16 Feb 22
Other Events
8:15am
8-K
ecl4nhuqeh z6rf
25 Jan 22
Regulation FD Disclosure
8:27am
8-K
ugoke2yqim
19 Jan 22
New award option exercised by BARDA brings the total potential funding from its existing contract with Spero up to $59.7 million
8:11am